News | Ultrasound Imaging | September 17, 2026

This issuances bring the company’s US patent portfolio to six, adding protection for methods to detect and measure drug exposure and to help identify, predict, and manage a wide range of medical conditions.

Ultrasound AI Receives Two New Patents

Sept. 16, 2026 — Ultrasound AI, Inc., a developer of artificial intelligence for medical imaging with a focus on maternal-fetal health, has announced the issuance of two U.S. patents, bringing its U.S. portfolio to six granted patents. Issued on Sept. 1 and Sept. 15, the patents address pharmaceutical-exposure analysis and comprehensive medical assessment through medical imaging.

The new patents expand the company’s intellectual property portfolio around using artificial intelligence to extract clinically relevant information from medical images. They reflect research extending from Ultrasound AI’s foundations in pregnancy imaging to additional potential applications in medicine.

“Our goal is to turn the information in medical images into insights that help clinicians make more informed decisions,” said Robert Bunn, founder and CEO of Ultrasound AI. “These patents reflect the breadth of our research and strengthen the intellectual property foundation for our work. Our focus remains bringing carefully developed AI into maternal-fetal care, where better information can make a meaningful difference for families.”

The two patents are:

  • U.S. Patent No. 12,721,589 B2, issued Sept. 1, 2026, titled Artificial Intelligence System for Determining Drug Use Through Medical Imaging. The patent describes methods for training neural networks to estimate pharmaceutical exposure from medical images, including selecting relevant imaging information and filtering images based on quality or usefulness to the analysis. 

  • U.S. Patent No. 12,733,901, issued Sept. 15, 2026, titled Artificial Intelligence System for Comprehensive Medical Diagnosis, Prognosis, and Treatment Optimization Through Medical Imaging. The invention describes approaches to analyzing medical images and underlying imaging data to generate information relevant to medical assessment, prognosis and treatment planning. 

The additions build on Ultrasound AI’s existing U.S. patents concerning premature-birth prediction and the determination of clinical values through medical imaging. The company also holds patents in Israel, Singapore, Japan and South Korea, with additional applications pending in the United States and internationally. The full patent portfolio can be found at ultrasound.ai/patents.

 

Issued patents cover inventions and methods, and do not reflect the FDA-authorized indications for use of any Ultrasound AI product.

 

Ultrasound AI patents

 


Additional Content

News | Radiology Imaging

Nov. 1, 2026 — GE HealthCare recently introduced Allia Celeo,* a ceiling-mounted image guiding system, at the ...

Time November 05, 2026
arrow
News | Radiology Imaging

Nov. 2, 2026 — Neurophet and RapidAI have partnered to integrate Neurophet’s advanced neurodegenerative brain imaging ...

Time November 04, 2026
arrow
News | Ultrasound Imaging

Oct. 28, 2026 — Clarius Mobile Health has announced 30 specialized AI models are now integrated into Clarius App 13.1 ...

Time November 02, 2026
arrow
News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | X-Ray

Oct. 27, 2026 — AZmed has announced that its FDA-cleared AZtrauma and AZchest X-ray AI applications are available ...

Time October 29, 2026
arrow
Subscribe Now